BRCA mutation carriers were reported to display a skewed distribution of FMR1 genotypes, predominantly within the low normal range (CGG repeat number o26). This observation led to the interpretation that BRCA1/2 mutations are embryo-lethal, unless rescued by 'low FMR1 alleles'. We undertook to re-explore the distribution of FMR1 alleles subdivided into low, normal and high (o26, 26-34, and 434 CGG repeats, respectively) subgenotypes, on a cohort of 125 Ashkenazi women, carriers of a BRCA1/2 founder mutation. Ashkenazi healthy females (n ¼ 368), tested in the frame of the Israeli screening population program, served as controls. BRCA1/2 carriers and controls demonstrated a comparable and non-skewed FMR1 subgenotype distribution. Taken together, using a homogeneous ethnic group of Ashkenazi BRCA1/2 mutation carriers, we could not confirm the reported association between FMR1 low genotypes and BRCA1/2 mutations. The notion that BRCA1/2 mutations are embryo-lethal unless rescued by the low FMR1 subgenotypes is hereby refuted. European Journal of Human Genetics ( Expansion of the CGG segment to the so-called pre-mutation range (approximately g.5061CGG (55_200)) is associated with neuropsychiatric risks and primary ovarian insufficiency. 1 The full mutation range g.5061CGG(4200) instigates gene inactivation and loss of FMR1 protein, thereby causing fragile X syndrome, an X-linked condition, the leading cause of inherited intellectual disability in humans. 2, 3 Gleicher et al 4-6 have constructed a 'private' classification of subgenotypes within the normal FMR1 range (up to 55 repeats). As such, they labeled alleles of 26-34 CGG repeats g.5061CGG(26_34) as 'normal' , alleles of less than 26 repeats as 'low range' g.5061CGG(5_25) and those of more than 34 repeats as 'high range' g.5061CGG(35_55). Repeats within the median range g.5061CGG(29_30) correspond allegedly with the switching point between positive and negative message and peak translation of the gene product of FMR1. [4] [5] [6] [7] Individuals were then defined as 'normal' if both alleles were in the 'normal' range, as 'heterozygous' if one allele was outside the 'normal' range and as homozygous if both alleles were outside of the range. These genotypes were further subdivided based on whether FMR1 alleles were above (high) or below (low) the normal range. [4] [5] [6] [7] 
INTRODUCTION
The fragile X mental retardation 1 (FMR1) gene, located on the long arm of the X chromosome, contains a repetitive CGGn trinucleotide segment in the 5 0 UTR region of the gene NG_007529.1:g.5061CGG (5_55). Most individuals demonstrate 29-30 CGG triple repeats, the normal range being defined at 5-55 repeats (median n ¼ 30). Expansion of the CGG segment to the so-called pre-mutation range (approximately g.5061CGG (55_200)) is associated with neuropsychiatric risks and primary ovarian insufficiency. 1 The full mutation range g.5061CGG(4200) instigates gene inactivation and loss of FMR1 protein, thereby causing fragile X syndrome, an X-linked condition, the leading cause of inherited intellectual disability in humans. 2, 3 Gleicher et al [4] [5] [6] have constructed a 'private' classification of subgenotypes within the normal FMR1 range (up to 55 repeats). As such, they labeled alleles of 26-34 CGG repeats g.5061CGG(26_34) as 'normal' , alleles of less than 26 repeats as 'low range' g.5061CGG(5_25) and those of more than 34 repeats as 'high range' g.5061CGG(35_55). Repeats within the median range g.5061CGG(29_30) correspond allegedly with the switching point between positive and negative message and peak translation of the gene product of FMR1. [4] [5] [6] [7] Individuals were then defined as 'normal' if both alleles were in the 'normal' range, as 'heterozygous' if one allele was outside the 'normal' range and as homozygous if both alleles were outside of the range. These genotypes were further subdivided based on whether FMR1 alleles were above (high) or below (low) the normal range. [4] [5] [6] [7] This classification was used to show that young women who have 'low or high' CGG counts, whether heterozygous or homozygous, have diminished ovarian reserve. 6, 7 The 29-30 CGG repeat range appears reflective of normal ovarian reserve, with higher and lower counts denoting similar risks towards premature ovarian senescence. [4] [5] [6] [7] Ultimately, the low range allele seems to be associated with premature ovarian aging, primary ovarian insufficiency, occult primary insufficiency, premature menopause, diminished ovarian reserve, and deficient follicle recruitment and IVF outcomes. [4] [5] [6] [7] Other than this, carriers of BRCA1/2 mutations, with breast cancer, were equally reported to endure primary ovarian insufficiency. 8 BRCA1/2 mutations and FMR1 genotypes, whether low-normal or in the permutation range, were independently reported to be associated with prematurely diminished ovarian reserve. 8 To test whether the observed effects of BRCA1/2 and FMR1 on ovaries were interrelated, Weghofer et al recently studied 99 women with BRCA1/2 mutations and showed that they preponderantly demonstrated the low FMR1 genotype (o26 CGG repeats) compared with the distribution displayed by a control population of 410 infertile women. 9 The authors argue that the plausible explanation for such a skewed distribution is that human BRCA1/2 mutations are likely embryo-lethal unless rescued by a low FMR1 subgenotype. 9 They conclude that women with BRCA1/2-associated breast cancer most likely carry the low FMR1 subgenotypes and that the reported risk towards prematurely diminished ovarian reserve is FMR1-mediated.
Using this data they generated a hypothesis maintaining that women with low alleles are expected to carry BRCA1/2 mutations whereas those carrying normal or high CGGn FMR1 alleles are expected to be BRCA1/2 mutation free. 9 In our Ashkenazi Jewish population, which is quite homogeneous, the prevalence of BRCA1/2 founder mutations, namely c.66_ 67delAG (185delAG) and c.5263_5264insC (5382insC) in BRCA1 (NM_007294.3) and c.5946delT (6174delT) in BRCA2 (NM_000059.3), reaches 2.5%. With all of the above in mind, we undertook to re-explore the distribution of FMR1 subgenotypes, in a cohort of Ashkenazi Jewish females, all carriers of one of the three BRCA1/2 founder mutations. 10 
MATERIALS AND METHOD

Study population
The study was approved by the Institutional Review Board, at Rambam Health Care Campus, Haifa, Israel. Patients, at time of initial consultation, signed an informed consent, which allows for review of medical records for research purposes as long as confidentiality of the medical record is maintained. All archive files at our Oncogenetic Hereditary Breast-Ovarian Clinic were reviewed in order to identify a study cohort consisting of Ashkenazi women who carried a BRCA1/2 mutation, whether affected (n ¼ 97) or non-affected (n ¼ 28) by cancer. BRCA1/2 carriers were counseled and tested at our Oncogenetic Clinic between the years1995 and 2012. Ashkenazi healthy female individuals (n ¼ 368), with no family history of developmental impairment, were screened for fragile X syndrome, at the Bnai-Zion Medical Center, Haifa, Israel in the frame of the Israeli screening population program, and selected to have less than 55 CGG repeats, served as a control group. Among the BRCA1/2 carriers: 61 and 19 carried the 185delAG and the 5382insC mutation in BRCA1, respectively; 46 had the 6174delT mutation in BRCA2 and one participant had both a 185delAG and a 6174delT mutation. The BRCA1/2 carrier group includes: 97 patients, of whom 66 had breast cancer, 21 had ovarian cancer and 10 had both breast and ovarian cancer; and 25 carrier females with no history of cancer. FMR1 CGGn repeats were tested in the 125 participants from the study group.
Genotyping
FMR1 alleles. FMR1 testing was performed by PCR amplification using previously described primers 11 with the GC-RICH PCR System (Roche Applied Science, Penzberg, Germany). Size fragment analysis was carried out by capillary electrophoresis in an ABI PRISM 3100 automatic sequencer (Applied Biosystems, Foster City, CA, USA). This methodology detects only alleles up to a maximum of 70 CGG repeats.
FMR1 data were reported for both alleles as CGGn repeats and as follows: normal range (CGG n ¼ 26-34), low range (less than 26 repeats), high range (between 34 and 55 repeats) and converted into subgenotypes as follows: homozygous (normal, low or high) and heterozygous (normal/low, normal/ high or high/low). BRCA1/2 ashkenazi mutations. The three predominant founder Ashkenazi mutation, namely, 185delAG and 5382insC in BRCA1; and 6174delT in BRCA2, are routinely tested in breast and/or ovarian cancer patients and family members at risk, at our oncogenetic diagnostic service at Rambam Health Care Campus, as from 1995, using RFLPs as previously described. 12, 13 Statistics. Proportions of FMR1 subgenotypes were compared among groups using cross-tabulations and calculations of Chi-square and t-test statistical test when appropriate at 5% significance level. All statistical calculations were performed using SPSS 19.0 version IBM (Armonk, NY, USA).
RESULTS
The distribution of FMR1 subgenotypes among BRCA1/2 carriers and healthy controls was comparable (Table 1 ) and as follows: homozygous normal 68.0% (n ¼ 85) and 55.7% (n ¼ 205), respectively; heterozygous normal/low 22.4% (n ¼ 28) and 26.4% (n ¼ 97), respectively; heterozygous normal/high 7.2% (n ¼ 9) and 11.7% (n ¼ 43), respectively; and heterozygous high/low 1.6% (n ¼ 2) and 3.8% (n ¼ 14), respectively. Table 2 describes the clinical characteristics of 125 BRCA1/2 mutation carriers related to FMR1 subgenotypes. It shows that BRCA1/2 carriers, with at least one low allele, do not differ from those with normal or high alleles as regards morbidity, age at cancer onset, type of BRCA1/2 mutation and family history of breastovarian-pancreatic cancer. Most BRCA1/2 carriers, diagnosed with breast cancer, harbored preferentially the 185delAG mutation and had a family history for hereditary breast-ovarian-pancreatic syndrome, irrespective of whether they had normal-high alleles or at least one low allele. Table 3 details the partition of BRCA1/2 mutations and FMR1 subgenotypes in study and control groups. Only 24.8% (n ¼ 31) of BRCA1/2 carriers exhibited one low allele comparable to 31.5% (n ¼ 116) of controls (P ¼ 0.156).
DISCUSSION
Diminished ovarian reserve has been independently reported in BRCA1/2 mutation carriers and in women carrying low FMR1 subgenotypes. [4] [5] [6] [7] [8] Weghofer et al hypothesized that the reported association of BRCA1/2 mutations with premature ovarian failure is FMR1-mediated and have lately unequivocally demonstrated that BRCA1/2 mutations are almost exclusively associated with the low FMR1 allele. 9 This observation was challenged by exploring the distribution of FMR1 subgenotypes in a cohort of Ashkenazi women, carriers of a BRCA1/2 founder mutation. We found that the FMR1 subgenotypes were equally distributed among our BRCA1/2 carriers of Ashkenazi descent compared with that observed in a control group from the same ethnic background.
Taken together, using a homogeneous group of Ashkenazi BRCA1/2 mutation carriers, we could not confirm the reported association between the low FMR1 subgenotype and BRCA1/2 mutations. The notion that BRCA1/2 mutations are embryo-lethal unless rescued by low FMR1 subgenotypes is hereby refuted. BRCA1/2 mutations were reported to be embryo-lethal only if affecting both alleles. 14 In addition, an international study conducted by us and colleagues, on 2828 BRCA1/2 carriers, asserts that BRCA1/2 mutation is not a risk factor for spontaneous abortions. 15 The high prevalence of BRCA1/2 founder mutations in the Ashkenazi population does not favor the assumption that BRCA1/2 mutation is embryo-lethal.
Lately, Brandao et al 16 and Ricci et al 17 have independently shown that the distribution of the FMR1 subgenotypes in BRCA mutation carriers compares well with that obtained from non carriers, concluding that BRCA1/2 mutations are not associated with FMR1 low subgenotypes.
Our case control study has been conducted on relatively large cohorts, from a defined homogenous population, that harbors a limited number of BRCA1/2 founder mutations. We can thus safely conclude that the observation asserting that women with breast cancer, carriers of a BRCA1/2 mutation, harbor preferentially a low FMR1 allele, is invalid. FMR1 normal or high CGG repeats compared with at least one low CGG repeats in the BRCA1/2 mutation carriers and controls.
